دورية أكاديمية
Update on the Management of Low-stage Seminoma.
| العنوان: | Update on the Management of Low-stage Seminoma. |
|---|---|
| المؤلفون: | Xia L; Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA 90089, USA. Electronic address: leilei.xia@med.usc.edu., Daneshmand S; Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA 90089, USA. |
| المصدر: | The Urologic clinics of North America [Urol Clin North Am] 2024 Aug; Vol. 51 (3), pp. 377-385. Date of Electronic Publication: 2024 Apr 09. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Saunders Country of Publication: United States NLM ID: 0423221 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-318X (Electronic) Linking ISSN: 00940143 NLM ISO Abbreviation: Urol Clin North Am Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, Saunders. |
| مواضيع طبية MeSH: | Seminoma*/therapy , Seminoma*/pathology , Testicular Neoplasms*/therapy , Testicular Neoplasms*/pathology , Neoplasm Staging*, Humans ; Male ; Lymph Node Excision ; Orchiectomy |
| مستخلص: | The contemporary paradigm of testicular cancer management is achieving high and durable cure rates while minimizing the burden of treatment given the potential long-term toxicities associated with radiation therapy and systemic therapies. The management of low-stage seminoma has seen significant changes in recent years. Nuances of surveillance strategies for stage I seminoma exist and continue to evolve. Emerging data show retroperitoneal lymph node dissection is a viable treatment option for selected patients with clinical stage IIA and IIB seminoma. Competing Interests: Disclosure The authors declare no commercial or financial conflicts of interest, or any funding sources related to this study. S. Daneshmand has Stock and Other Ownership Interests with Taris, Honoraria: Photocure, QED Therapeutics, Olympus, Ferring, Pacific Edge, Urogene, Johnson & Johnson, Janssen, Bristol Myers Squibb, and Allergan. S. Daneshmand served in Consulting or Advisory Role for Photocure, Taris, Ferring, and QED Therapeutics. Travel, Accommodations, and Expenses: Photocure. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Chemotherapy; Germ cell tumor; MicroRNA-371a-3p; Radiotherapy; Retroperitoneal lymph node dissection; Seminoma; Surveillance; Testicular cancer |
| تواريخ الأحداث: | Date Created: 20240626 Date Completed: 20240626 Latest Revision: 20240626 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1016/j.ucl.2024.03.006 |
| PMID: | 38925740 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1558-318X |
|---|---|
| DOI: | 10.1016/j.ucl.2024.03.006 |